FIND

WHO and FIND: Technical guide on sequencing

Read More →

FIND, WHO and partners create framework for test that predicts progression of TB

29 November 2017: The End TB Strategy introduced by the World Health Organization (WHO) and adopted by the World Health Assembly aims to reduce TB related deaths by 95% and new TB infections by 90% by 2035. Approximately one quarter to one third of the world’s population is currently infected with the M. tuberculosis bacteria and the risk of developing an active form of the disease among infected individuals is between 5 and 15 percent.

Read More →

Work plan template for Xpert MTB/RIF® implementation and scale-up

The work plan template is intended to guide the implementation of Xpert MTB/RIF testing in facilities providing clinical services.

Read More →

FIND signs partnership agreement with McGill on TB diagnostics

FIND is pleased to announce the finalization of a memorandum of understanding with the Research Institute of the McGill University Health Centre in Montreal, with a focus on tuberculosis (TB) diagnostics.

Read More →

FIND and Cepheid announce a strategic collaboration to advance point-of-care TB diagnosis

CAPE TOWN, South Africa and GENEVA and SUNNYVALE, Calif., Dec. 3, 2015 -- FIND and Cepheid today announced that they are broadening their collaboration on bringing point-of-care tuberculosis (TB) diagnosis to all levels of the health system in low and middle-income countries (LMICs). The work under the collaboration will focus on evaluating and implementing Cepheid's new GeneXpert® Omni system and Xpert® MTB/RIF Ultra test, in addition to assessing the system's cloud-based connectivity. These efforts will ultimately benefit all stakeholders, as the resulting data and know-how will be made publicly available.

Read More →

Brazil, China, India and South Africa offer big opportunities for TB diagnostics

A new report from FIND, McGill International TB Centre, and UNITAID, entitled “TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities for Novel Diagnostics”, notes that there is already a sizeable TB diagnostic market in these four countries.

Read More →

FIND and QuantuMDx partnering to developing breakthrough technology for tuberculosis detection and drug resistance determination

24 October 2014. Geneva and Newcastle upon Tyne, UK: FIND, a Geneva-based non-profit organization and QuantuMDx Group, a British medical device developer are joining forces in developing a paradigm changing solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis. Based on the molecular detection of an extensive set of genetic markers by the simple handheld Q-POC™ device developed by QuantuMDx, the time for full antimycobacterial resistance profiling will be reduced from weeklong to less than half an hour. The uniqueness of the nanowire technology developed by QuantuMDx provides the potential to interrogate the bacterial genome with unprecedented precision, as it allows not only targeted detection of specific markers, but in addition (in a future evolution of the present system) genetic sequencing on the same technology platform. As part of this partnership, FIND is supporting the development of an appropriate and integrated sample handling compartment, while QuantuMDx continues its platform development.

Read More →

Cepheid, FIND & Rutgers announce collaboration for next-generation innovations to game-changing Xpert MTB/RIF test

Xpert MTB/RIF Ultra, the next-generation test for Mycobacterium tuberculosis, will be with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection.

Read More →

FIND is appointed as WHO Collaborating Centre

The four-year appointment acknowledges the role FIND plays in evaluating and introducing new TB diagnostic solutions and building laboratory capacity needed to effectively control TB.

Read More →

Progress in diagnosing multidrug-resistant tuberculosis

Innovative project expands access to new test: the project known as EXPAND-TB helped to triple the number of MDR-TB cases diagnosed in participating countries.

Read More →

Page 1 of 1 · Total posts: 10

1